GC Pharma (KRX: 006280), a South Korean biopharmaceutical company, announced on Wednesday its unaudited results for the year ended 31 December 2019.
The company reported total revenues of KRW1,369.7bn in 2019, up 2.6% compared to 2018.
Operating profit decreased 19.7% to KRW40.3bn (2018: KRW 41.9bn), primarily due to an impact of investment in R&D and SG&A.
One off costs - including corporate tax bill and VAT result in regular tax investigation, evaluation loss of stock investment, impairment losses of tangible asset and penalties from local antitrust regulator related to subsidiary, Green Cross MS, and impairment losses of intangible assets - impacted on after tax profits, expected to progressively ease over the course of 2020.
(USD1=KRW1.183)
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development